

Jeannette Lechner-Scott

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4239378/publications.pdf>

Version: 2024-02-01

191
papers

10,388
citations

61857

43
h-index

37111

96
g-index

197
all docs

197
docs citations

197
times ranked

13399
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. <i>Nature</i> , 2011, 476, 214-219.	13.7	2,400
2	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. <i>Nature Genetics</i> , 2013, 45, 1353-1360.	9.4	1,213
3	Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 127-137.	0.9	422
4	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 175.	3.8	336
5	Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016, 139, 2395-2405.	3.7	281
6	MicroRNAs miR-17 and miR-20a Inhibit T Cell Activation Genes and Are Under-Expressed in MS Whole Blood. <i>PLoS ONE</i> , 2010, 5, e12132.	1.1	225
7	Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. <i>PLoS ONE</i> , 2012, 7, e48078.	1.1	166
8	Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , 2015, 138, 3287-3298.	3.7	162
9	Predictors of long-term disability accrual in relapse-onset multiple sclerosis. <i>Annals of Neurology</i> , 2016, 80, 89-100.	2.8	158
10	The COVID-19 pandemic and the use of MS disease-modifying therapies. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 102073.	0.9	153
11	Predictors and dynamics of postpartum relapses in women with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 739-746.	1.4	148
12	Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 2015, 77, 425-435.	2.8	143
13	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. <i>Brain</i> , 2013, 136, 3609-3617.	3.7	140
14	Fingolimod after natalizumab and the risk of short-term relapse. <i>Neurology</i> , 2014, 82, 1204-1211.	1.5	138
15	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 271-281.	4.9	134
16	The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. <i>Human Molecular Genetics</i> , 2010, 19, 2134-2143.	1.4	128
17	Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. <i>PLoS ONE</i> , 2015, 10, e0122686.	1.1	122
18	Methylation differences at the <i>HLA-DRB1</i> locus in CD4+ T-Cells are associated with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1033-1041.	1.4	120

#	ARTICLE	IF	CITATIONS
19	Incidence and prevalence of NMOSD in Australia and New Zealand. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 632-638.	0.9	108
20	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 405.	4.5	100
21	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017, 140, 2426-2443.	3.7	94
22	NLRP3 inflammasome is associated with the response to IFN- β in patients with multiple sclerosis. <i>Brain</i> , 2015, 138, 644-652.	3.7	93
23	Genome-wide DNA methylation profiling of CD8+ T cells shows a distinct epigenetic signature to CD4+ T cells in multiple sclerosis patients. <i>Clinical Epigenetics</i> , 2015, 7, 118.	1.8	85
24	Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1133-1137.	0.9	76
25	Risk of relapse phenotype recurrence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1511-1522.	1.4	73
26	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 458-468.	0.9	71
27	Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. <i>Annals of Neurology</i> , 2014, 76, 880-890.	2.8	67
28	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1343-1349.	0.9	63
29	Differential methylation at MHC in CD4+ T cells is associated with multiple sclerosis independently of HLA-DRB1. <i>Clinical Epigenetics</i> , 2017, 9, 71.	1.8	63
30	On the origin of Neurostatus. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 182-185.	0.9	62
31	Epigenome-wide association studies: current knowledge, strategies and recommendations. <i>Clinical Epigenetics</i> , 2021, 13, 214.	1.8	62
32	Comparative efficacy of switching to natalizumab in active multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 373-387.	1.7	57
33	The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. <i>Multiple Sclerosis Journal</i> , 2012, 18, 974-982.	1.4	56
34	A Polymorphism in the HLA-DPB1 Gene Is Associated with Susceptibility to Multiple Sclerosis. <i>PLoS ONE</i> , 2010, 5, e13454.	1.1	55
35	Potential association of vitamin D receptor polymorphism <i>Taq1</i> with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 16-22.	1.4	55
36	Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. <i>Brain</i> , 2015, 138, 632-643.	3.7	54

#	ARTICLE	IF	CITATIONS
37	A comparative analysis of Patient-Reported Expanded Disability Status Scale tools. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1349-1358.	1.4	54
38	Evaluation of MS related central fatigue using MR neuroimaging methods: Scoping review. <i>Journal of the Neurological Sciences</i> , 2019, 400, 52-71.	0.3	54
39	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , 2021, 96, e783-e797.	1.5	54
40	A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis. <i>Human Molecular Genetics</i> , 2015, 24, 5644-5654.	1.4	53
41	Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 79-90.	1.4	52
42	A Transcription Factor Map as Revealed by a Genome-Wide Gene Expression Analysis of Whole-Blood mRNA Transcriptome in Multiple Sclerosis. <i>PLoS ONE</i> , 2010, 5, e14176.	1.1	51
43	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 196-203.	0.9	49
44	Anxiety, depression and fatigue at 5-year review following CNS demyelination. <i>Acta Neurologica Scandinavica</i> , 2016, 134, 403-413.	1.0	47
45	Ongoing increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: A 50-year study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1063-1071.	1.4	45
46	Predictors of disability worsening in clinically isolated syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 479-491.	1.7	43
47	Next-generation sequencing reveals broad down-regulation of microRNAs in secondary progressive multiple sclerosis CD4+ T cells. <i>Clinical Epigenetics</i> , 2016, 8, 87.	1.8	43
48	EBV and MS: Major cause, minor contribution or red-herring?. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 16, 24-30.	0.9	43
49	Genome-wide DNA methylation changes in CD19+ B cells from relapsing-remitting multiple sclerosis patients. <i>Scientific Reports</i> , 2018, 8, 17418.	1.6	42
50	Polymorphisms in the Receptor Tyrosine Kinase MERTK Gene Are Associated with Multiple Sclerosis Susceptibility. <i>PLoS ONE</i> , 2011, 6, e16964.	1.1	42
51	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. <i>Neurology</i> , 2021, 96, .	1.5	41
52	The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform. <i>PLoS ONE</i> , 2013, 8, e59694.	1.1	38
53	The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 305-310.	0.9	37
54	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 642-652.	1.4	37

#	ARTICLE	IF	CITATIONS
55	Increased DNA methylation of SLFN12 in CD4+ and CD8+ T cells from multiple sclerosis patients. PLoS ONE, 2018, 13, e0206511.	1.1	37
56	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1159-1171.	1.4	36
57	A comparison between the pathophysiology of multiple sclerosis and normal pressure hydrocephalus: is pulse wave encephalopathy a component of MS?. Fluids and Barriers of the CNS, 2016, 13, 18.	2.4	36
58	Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1617-1626.	1.4	36
59	Increasing age at disability milestones among MS patients in the MSBase Registry. Journal of the Neurological Sciences, 2012, 318, 94-99.	0.3	35
60	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Multiple Sclerosis and Related Disorders, 2019, 28, 235-243.	0.9	35
61	Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. PLoS ONE, 2012, 7, e38661.	1.1	35
62	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 520-532.	1.4	34
63	Prognostic indicators in pediatric clinically isolated syndrome. Annals of Neurology, 2017, 81, 729-739.	2.8	34
64	Comparative efficacy of first-line natalizumab vs IFN- β or glatiramer acetate in relapsing MS. Neurology: Clinical Practice, 2016, 6, 102-115.	0.8	33
65	Uveitis and optic perineuritis in the context of myelin oligodendrocyte glycoprotein antibody seropositivity. European Journal of Neurology, 2019, 26, 1137.	1.7	33
66	<sc>BREMSO</sc>: a simple score to predict early the natural course of multiple sclerosis. European Journal of Neurology, 2015, 22, 981-989.	1.7	32
67	Contribution of different relapse phenotypes to disability in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 266-276.	1.4	30
68	Natural killer cell subpopulations are associated with MRI activity in a relapsing-remitting multiple sclerosis patient cohort from Australia. Multiple Sclerosis Journal, 2017, 23, 1479-1487.	1.4	30
69	Sun Exposure across the Life Course Significantly Modulates Early Multiple Sclerosis Clinical Course. Frontiers in Neurology, 2018, 9, 16.	1.1	30
70	The emerging role of artificial intelligence in multiple sclerosis imaging. Multiple Sclerosis Journal, 2022, 28, 849-858.	1.4	30
71	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2020, 38, 101868.	0.9	29
72	Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. Pharmacogenomics Journal, 2017, 17, 312-318.	0.9	28

#	ARTICLE	IF	CITATIONS
73	Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation. <i>Frontiers in Neurology</i> , 2020, 11, 537.	1.1	27
74	Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e63480.	1.1	26
75	A non-synonymous SNP within membrane metalloendopeptidase-like 1 (MMEL1) is associated with multiple sclerosis. <i>Genes and Immunity</i> , 2010, 11, 660-664.	2.2	25
76	The Audio Recorded Cognitive Screen (ARCS) in patients with multiple sclerosis: a practical tool for multiple sclerosis clinics. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1126-1133.	1.4	24
77	Fast magnetic resonance spectroscopic imaging techniques in human brain- applications in multiple sclerosis. <i>Journal of Biomedical Science</i> , 2017, 24, 17.	2.6	24
78	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756.	3.7	24
79	Lack of support for association between the KIF1B rs10492972[C] variant and multiple sclerosis. <i>Nature Genetics</i> , 2010, 42, 469-470.	9.4	23
80	Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, downregulated by interferon treatment, and affected by season. <i>Multiple Sclerosis Journal</i> , 2014, 20, 675-685.	1.4	23
81	Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy. <i>Multiple Sclerosis Journal</i> , 2021, 27, 465-474.	1.4	23
82	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1847-1856.	0.8	22
83	Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. <i>Journal of the Neurological Sciences</i> , 2018, 391, 72-76.	0.3	22
84	Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. <i>European Journal of Neurology</i> , 2016, 23, 729-736.	1.7	21
85	Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine. <i>Multiple Sclerosis Journal</i> , 2016, 22, 944-954.	1.4	21
86	Anxiety Levels Are Independently Associated With Cognitive Performance in an Australian Multiple Sclerosis Patient Cohort. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2017, 29, 128-134.	0.9	21
87	Association of Pregnancy With the Onset of Clinically Isolated Syndrome. <i>JAMA Neurology</i> , 2020, 77, 1496.	4.5	21
88	Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 208, 106180.	2.6	21
89	Resequencing and fine-mapping of the chromosome 12q13-14 locus associated with multiple sclerosis refines the number of implicated genes. <i>Human Molecular Genetics</i> , 2013, 22, 2283-2292.	1.4	20
90	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2018, 75, 1407.	4.5	20

#	ARTICLE	IF	CITATIONS
91	Altered in vivo brain GABA and glutamate levels are associated with multiple sclerosis central fatigue. <i>European Journal of Radiology</i> , 2021, 137, 109610.	1.2	20
92	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1857-1865.	0.8	19
93	Pharmacogenomic study in patients with multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e154.	3.1	19
94	IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2011, 239, 101-104.	1.1	18
95	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1346-1357.	1.4	18
96	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 11-19.	0.9	17
97	DNA methylation changes in CD4 ⁺ T cells isolated from multiple sclerosis patients on dimethyl fumarate. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731878782.	0.5	17
98	The clinical profile of NMOSD in Australia and New Zealand. <i>Journal of Neurology</i> , 2020, 267, 1431-1443.	1.8	17
99	Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS. <i>Neurology: Clinical Practice</i> , 2020, 10, 510-519.	0.8	17
100	Comparison of the sagittal sinus cross-sectional area between patients with multiple sclerosis, hydrocephalus, intracranial hypertension and spontaneous intracranial hypotension: a surrogate marker of venous transmural pressure?. <i>Fluids and Barriers of the CNS</i> , 2017, 14, 18.	2.4	16
101	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1835-1846.	0.8	15
102	Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e869-e880.	1.5	15
103	Letter to the editor: blood processing and sample storage have negligible effects on methylation. <i>Clinical Epigenetics</i> , 2018, 10, 22.	1.8	14
104	Erythrocyte microRNA sequencing reveals differential expression in relapsing-remitting multiple sclerosis. <i>BMC Medical Genomics</i> , 2018, 11, 48.	0.7	12
105	Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. <i>European Journal of Neurology</i> , 2019, 26, 363-370.	1.7	12
106	The Incidence of Transverse Sinus Stenosis in Multiple Sclerosis: Further Evidence of Pulse Wave Encephalopathy. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102524.	0.9	12
107	COVID-19 vaccines and multiple sclerosis disease-modifying therapies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103155.	0.9	12
108	Automatic and Robust Segmentation of Multiple Sclerosis Lesions with Convolutional Neural Networks. <i>Computers, Materials and Continua</i> , 2020, 66, 977-991.	1.5	12

#	ARTICLE	IF	CITATIONS
109	Favourable Outcome in a 33-Year-Old Female with Acute Haemorrhagic Leukoencephalitis. Case Reports in Neurology, 2017, 9, 106-113.	0.3	11
110	NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients. Multiple Sclerosis Journal, 2018, 24, 1507-1510.	1.4	11
111	The effect of emerging nutraceutical interventions for clinical and biological outcomes in multiple sclerosis: A systematic review. Multiple Sclerosis and Related Disorders, 2020, 37, 101486.	0.9	11
112	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 755-766.	1.4	11
113	Is EBV the cause of multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2022, 58, 103636.	0.9	11
114	Fluctuations of MS births and UV-light exposure. Acta Neurologica Scandinavica, 2013, 127, 301-308.	1.0	10
115	Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation. Multiple Sclerosis Journal, 2013, 19, 1268-1274.	1.4	10
116	A new era in the treatment of multiple sclerosis. Medical Journal of Australia, 2015, 203, 139-141.	0.8	10
117	Erythrocytes in multiple sclerosis – forgotten contributors to the pathophysiology?. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2016, 2, 205521731664998.	0.5	10
118	Diurnal variability of cerebral metabolites in healthy human brain with 2D localized correlation spectroscopy (2D L-COSY). Journal of Magnetic Resonance Imaging, 2019, 50, 592-601.	1.9	10
119	Diurnal stability and long-term repeatability of neurometabolites using single voxel 1H magnetic resonance spectroscopy. European Journal of Radiology, 2018, 108, 107-113.	1.2	9
120	Epigenetic differences at the HTR2A locus in progressive multiple sclerosis patients. Scientific Reports, 2020, 10, 22217.	1.6	9
121	Silent lesions on MRI imaging – Shifting goal posts for treatment decisions in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1569-1577.	1.4	8
122	Onset Symptoms, Tobacco Smoking, and Progressive-Onset Phenotype Are Associated With a Delayed Onset of Multiple Sclerosis, and Marijuana Use With an Earlier Onset. Frontiers in Neurology, 2018, 9, 418.	1.1	8
123	Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2019, 33, A1-A2.	0.9	8
124	2D in-vivo L-COSY spectroscopy identifies neurometabolite alterations in treated multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641987708.	1.5	8
125	Concentrations of plasma-borne extracellular particles differ between multiple sclerosis disease courses and compared to healthy controls. Multiple Sclerosis and Related Disorders, 2020, 45, 102446.	0.9	8
126	Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 42, 102259.	0.9	8

#	ARTICLE	IF	CITATIONS
127	Probing the association between Multiple Sclerosis and Epstein Barr Virus from a therapeutic perspective. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 103087.	0.9	8
128	The effectiveness of natalizumab vs fingolimod – A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103012.	0.9	8
129	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021, 35, 1217-1232.	2.7	8
130	MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 722237.	1.1	8
131	Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103385.	0.9	8
132	Multiple Sclerosis Relapses Following Cessation of Fingolimod. <i>Clinical Drug Investigation</i> , 2022, 42, 355-364.	1.1	8
133	Reduced cognitive function contributes to economic burden of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 60, 103707.	0.9	8
134	Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1800-1808.	1.4	7
135	Spiral MRSI and tissue segmentation of normal-appearing white matter and white matter lesions in relapsing remitting multiple sclerosis patients†. <i>Magnetic Resonance Imaging</i> , 2020, 74, 21-30.	1.0	7
136	Erythrocyte microRNAs show biomarker potential and implicate multiple sclerosis susceptibility genes. <i>Clinical and Translational Medicine</i> , 2020, 10, 74-90.	1.7	7
137	Comparison of BICAMS and ARCS for assessment of cognition in multiple sclerosis and predictive value of employment status. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102037.	0.9	7
138	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. <i>Multiple Sclerosis Journal</i> , 2021, 27, 695-705.	1.4	7
139	Validation of a Flow Cytometry Live Cell-Based Assay to Detect Myelin Oligodendrocyte Glycoprotein Antibodies for Clinical Diagnostics. <i>journal of applied laboratory medicine, The</i> , 2022, 7, 12-25.	0.6	7
140	Association Between Cognitive Trajectories and Disability Progression in Patients With Relapsing-Remitting Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e2020-e2031.	1.5	7
141	Possible Markers of Venous Sinus Pressure Elevation in Multiple Sclerosis: Correlations with Gender and Disease Progression. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 55, 103207.	0.9	7
142	Developing a clinical – environmental – genotypic prognostic index for relapsing-onset multiple sclerosis and clinically isolated syndrome. <i>Brain Communications</i> , 2021, 3, fcab288.	1.5	7
143	Can a stress management programme reduce stress and improve quality of life in people diagnosed with multiple sclerosis?. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731881317.	0.5	6
144	Prediction of multiple sclerosis outcomes when switching to ocrelizumab. <i>Multiple Sclerosis Journal</i> , 2022, 28, 958-969.	1.4	6

#	ARTICLE	IF	CITATIONS
145	Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2015, 1, 205521731560019.	0.5	5
146	A pharmacogenetic study implicates NIN2 in the response to Interferon- β in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1074-1082.	1.4	5
147	B cell therapy and the use of RNA-based COVID-19 vaccines. Multiple Sclerosis and Related Disorders, 2021, 49, 102887.	0.9	5
148	NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand. Journal of Neurology, 2022, 269, 836-845.	1.8	5
149	Reliability of neurometabolite detection with two-dimensional localized correlation spectroscopy at 3T. Journal of Magnetic Resonance Imaging, 2018, 48, 1559-1569.	1.9	4
150	Do people with multiple sclerosis receive appropriate support from the National Disability Insurance Scheme matching their level of disability? A description of disease "burden and societal cost in people with multiple sclerosis in Australia" (BAC-MS). Australian Health Review, 2021, 45, 745-752.	0.5	4
151	Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study). JMIR Research Protocols, 2021, 10, e24969.	0.5	4
152	CD4 ⁺ T-cell DNA methylation changes during pregnancy significantly correlate with disease-associated methylation changes in autoimmune diseases. Epigenetics, 2022, 17, 1040-1055.	1.3	4
153	Neural diffusion tensor imaging metrics correlate with clinical measures in people with relapsing-remitting MS. Neuroradiology Journal, 2022, 35, 592-599.	0.6	4
154	Common genetic variants in the plasminogen activation pathway are not associated with multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 489-491.	1.4	3
155	Multiple sclerosis and migration revisited. Multiple Sclerosis and Related Disorders, 2019, 34, A1-A2.	0.9	3
156	Multiple Sclerosis and Vitamin D "Caviar or a Dog's Dinner?". Multiple Sclerosis and Related Disorders, 2019, 28, A1-A2.	0.9	3
157	Determinants of therapeutic lag in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1838-1851.	1.4	3
158	Air pollution and multiple sclerosis risk. Multiple Sclerosis and Related Disorders, 2021, 48, 102797.	0.9	3
159	Does the venous pressure theory of multiple sclerosis pathophysiology deserve a second chance?. Multiple Sclerosis and Related Disorders, 2021, 56, 103262.	0.9	3
160	Subjective versus objective performance in people with multiple sclerosis using the MSReactor computerised cognitive tests.. Multiple Sclerosis and Related Disorders, 2022, 58, 103393.	0.9	3
161	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Pharmacoeconomics, 2022, 40, 323-339.	1.7	3
162	Automatic Prediction of the Conversion of Clinically Isolated Syndrome to Multiple Sclerosis Using Deep Learning. , 2018, , .		2

#	ARTICLE	IF	CITATIONS
163	068â€¦Evaluation of the long-term treatment effect of teriflunomide on cognitive outcomes and association with brain volume change: data from temso and its extension study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A28.1-A28.	0.9	2
164	Silent symptoms of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101453.	0.9	2
165	Is multiple sclerosis a risk factor for infections?. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102184.	0.9	2
166	Biochemical Correlations with Fatigue in Multiple Sclerosis Detected by MR 2D Localized Correlated Spectroscopy. <i>Journal of Neuroimaging</i> , 2021, 31, 508-516.	1.0	2
167	Can serum glial fibrillary acidic protein (GFAP) solve the longstanding problem of diagnosis and monitoring progressive multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102931.	0.9	2
168	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. <i>Multiple Sclerosis Journal</i> , 2022, , 135245852210845.	1.4	2
169	Prediction of Conversion from CIS to Clinically Definite Multiple Sclerosis Using Convolutional Neural Networks. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-8.	0.7	2
170	002â€¦Therapeutic lag in relapsing multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, A1.2-A1.	0.9	1
171	Should our treatment target in MS include the intrathecal plasma cell response?. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, A1-A2.	0.9	1
172	The MSReactor computerized cognitive battery correlates with the processing speed test in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102212.	0.9	1
173	Ageing and multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101953.	0.9	1
174	008â€¦Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis. , 2021, , .		1
175	Quantified hemodynamic parameters of the venous system in multiple sclerosis: A systematic review. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103477.	0.9	1
176	Capturing SNP Association across the NK Receptor and HLA Gene Regions in Multiple Sclerosis by Targeted Penalised Regression Models. <i>Genes</i> , 2022, 13, 87.	1.0	1
177	Confirmed disability progression as a marker of permanent disability in multiple sclerosis. <i>European Journal of Neurology</i> , 2022, , .	1.7	1
178	22. Enterovirus meningitis in a patient treated with Natalizumab. <i>Journal of Clinical Neuroscience</i> , 2009, 16, 1531-1532.	0.8	0
179	One size doesn't fit all. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 31, A1-A2.	0.9	0
180	Three suggestions to decrease the financial burden of MS treatments. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 30, A1.	0.9	0

#	ARTICLE	IF	CITATIONS
181	Acute flaccid myelitis in the 21st century: reminiscence of poliomyelitis or a new emergent disease. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 29, A1-A2.	0.9	0
182	131â€¦CLADIN: CLADribine and INNate immune responses. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, A42.3-A42.	0.9	0
183	134â€¦Cladribine: a multicentre long-term efficacy biomarker australian study (CLOBAS). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, A43.3-A43.	0.9	0
184	Grassroot efforts towards diversity in MS care and research: Win-win for patients and science. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, A1-A2.	0.9	0
185	â€œRocking the boatâ€ with a new drug for neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102458.	0.9	0
186	004â€¦Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis. , 2021, , .		0
187	011â€¦Worsening longitudinal reaction time trajectories using the MSReactor computerised battery predicts confirmed EDSS progression. , 2021, , .		0
188	Dare we mention the C-word?. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102340.	0.9	0
189	Response to treatment in NMOSD: the Australasian experience. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 58, 103408.	0.9	0
190	It is time to move to alternative clinical trial designs: Reconsidering the holy grail of trial methodology. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103426.	0.9	0
191	High efficacy treatment is not enough in MS: Socioeconomic factors are key to improving outcomes. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103816.	0.9	0